Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 220-290-4 | CAS number: 2702-72-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- GLP - Guideline study, tested with the source substance Dimethylammonium 2,4-dichlorophenoxyacetate (CAS No. 2008-39-1). In accordance to the ECHA guidance document “Practical guide 6: How to report read-across and categories (March 2010)”, the reliability was changed from RL1 to RL2 to reflect the fact that this study was conducted on a read-across substance.
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 996
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: EPA-Pesticide Assessment Guidelines, Subdivision F, Hazard Evaluation, Human and Domestic Animals, Series 82-1, 83-1, and 82, revised ed., November, 1984, US Department of Commerce, National Technical Information Service PB86-108958.
- Deviations:
- not specified
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Dimethylammonium 2,4-dichlorophenoxyacetate
- EC Number:
- 217-915-8
- EC Name:
- Dimethylammonium 2,4-dichlorophenoxyacetate
- Cas Number:
- 2008-39-1
- IUPAC Name:
- N-methylmethanaminium (2,4-dichlorophenoxy)acetate
- Details on test material:
- - Name of test material (as cited in study report):2,4-D dimethylamine salt, DMA
- Physical state: technical grade aqueous solution
- Analytical purity: 66.2% active ingredient
- Source of the test substance. Industry Task Force II on 2,4-D Research Data
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Raleigh, NC
- Age at study initiation: 4 weeks
- Housing: individually in elevated stainless steel, wire-mesh cages
- Diet: Purina certified rodent chow 5 002, ad libitum
- Water: ad libitum
- Acclimation period: at least 7 days
ENVIRONMENTAL CONDITIONS
- Photoperiod (hrs dark / hrs light): 12 /12
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- acetone
- Details on oral exposure:
- DIET PREPARATION
- Rate of preparation of diet (frequency): weekly
- Mixing appropriate amounts with (Type of food): Purina certified rodent chow 5 002 - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Homogeneity and stability of DMA in the diets were analytically verified by gas chromatography.
Concentration analyses of the dietary formulations for each group were determined weekly till the end of the study.
They indicated that all diets were homogeneous and within ±10% of targeted concentrations. DMA intakes were generally within ±10% of targeted doses, as calculated from the diet concentration analyses, the actual food consumption, and body weight measurements. - Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- Feed mixed with the test substance was available ad libitum
Doses / concentrations
- Remarks:
- Doses / Concentrations:
1, 15, 100 and 300 mg/kg bw/day (acid equivalent)
Basis:
nominal in diet
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Dose selection was based on the results of a previous short-time testing (Gorzinski et al. 1987)
- Rationale for animal assignment (if not random): Animals were randomly assigned by a weight randomization computer program designed to ensure homogenicity of body weights
- Animal selection. Animals were selected based on the examination of a veterinarian.
Examinations
- Observations and examinations performed and frequency:
- Toxicity, moribundity, and mortality were observed at least twice daily.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: weekly
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Time schedule: weekly
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Ophthalmoscopic examinations were conducted prior to treatment and at the end of the study (week 13).
HAEMATOLOGY: Yes
- Time schedule for collection of blood: hematology was performed during weeks 6 and 13
- Anaesthetic used for blood collection: Yes, blood samples were collected by orbital sinus venipuncture under ketamine hydrochloride anesthesia
- Animals fasted: Yes, over night
- Parameters checked: cell morphology, corrected leukocyte count, erythrocyte count, hematocrit, hemoglobin, leukocyte count,
leukocyte differential, and platelet count
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: clinical chemistry was performed during weeks 6 and 13
- Animals fasted: Yes, over night
- Parameters checked: alanine aminotransferase (ALT), albumin, aspartate aminotransferase (AST), blood urea nitrogen (BUN),
lactate dehydrogenase (LDH), alkaline phosphatase, calcium, chloride, creatinine, globulin, glucose, inorganic phosphorus, potassium, sodium,
total bilirubin, total cholesterol, total protein, triiodothyronine (T3), and thyroxine (T4)
URINALYSIS: Yes
- Time schedule for collection of urine: Collection of urine was performed during weeks 6 and 13
- Metabolism cages used for collection of urine: Yes, urine samples were collected over night in urine collection cages
- Animals fasted: Yes
- Parameters checked: bilirubin, glucose, ketones, pH, protein, specific gravity, and urobilinogen
OTHER:
Clinical pathology was performed during weeks 6 and 13 - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
- All animals sacrificed at study termination (week 13) were anesthetized by sodium pentobarbital, exsanguinated, and subjected
to gross and microscopic examinations. A complete necropsy was performed on all animals.
Following organs were weight: adrenals, brain, heart, kidneys, liver, ovaries, pituitary, testes (with epididymides), thymus, and thyroid/parathyroids
HISTOPATHOLOGY: Yes
The following tissues from each animal were preserved in 10% neutral-buffered Formalin:
adrenals, aorta, bone marrow (stemum), brain with brain stem, cecum, esophagus, eyes (fixed in Bouin's and stored in 70% alcohol), femur, heart, kidneys, duodenum, jejunum, ileum, colon, rectum, lacrimal gland, liver, lung, mammary gland, mesenteric lymph nodes, ovaries, pancreas, pituitary, salivary gland, sciatic nerve, skeletal muscle, spinal cord (three levels), spleen, stomach, testes with epididymides, thymus,
thyroid/parathyroids, trachea, urinary bladder, uterus, and any other tissues with gross lesions.
Preserved tissues were embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically. - Statistics:
- Different tests were performed (e.g. Bartlett, Levene, Dunnett).
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- adverse
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not specified
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- non adverse
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- non adverse
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- non adverse
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- CLINICAL SIGNS AND MORTALITY:
The test substance was relatively well tolerated and no treatment related deaths or illnesses were stated.
BODY WEIGHT AND WEIGHT GAIN AND FOOD CONSUMPTION:
Severe body weight gain depressions were observed at the dose level of 300 mg acid equivalents/kg/day.
The rates of body weight gain and food consumption were retarded in certain groups of treated animals of both sexes when compared with controls.
For males this depression ranged from 37 to 80% of controls; for females the range was 57 to 88%.
The no-observed-effect level (NOEL) for body weight and food consumption effects for DMA was considered to be 100 mg/kg bw/day (acid equivalent).
HAEMATOLOGY AND CLINICAL CHEMISTRY:
Clinical chemistry, hematology, and urine-analysis were performed during weeks 6 and 13. Changes in red cell mass, platelet count, T3, and T4 were observed. Blood urea nitrogen (BUN) was increased in the high dose animals (females) whereas the haemoglobin concentration was reduced at this concentration. 100 mg/kg bw/day (acid equivalent) significantly reduced the T3 and T4 levels (females), the red blood cell count (females), and platelet counts (females).
The NOEL for hematology and clinical chemistry effects was set to 15 mg/kg bw/day (acid equivalent).
ORGAN WEIGHTS:
Effects of DMA were determined for liver, kidney, testes and thyroid. The thyroid/ bw ratio and the liver weight was significantly increased in the high dose animals (male and female). Furthermore, inkreased kidney weight was observed in animal streated with 100 mg/kg bw/day (acid equivalent)(male and female). The weight of the testes of the male rats was significantly reduced in the highest dose group but unaffected in the other treatment groups. The NOEL for organ weight effects was set to 15 mg acid equivalents/kg/day.
GROSS PATHOLOGY AND HISTOPATHOLOGY: NON-NEOPLASTIC:
Histological alterations were observed predominantly at the 300 mg/kg bw/day (acid equivalent) group and consisted of retinal degeneration and
cataract formation (females), centrilobular hepatocellular hypertrophy (both sexes), atrophy of the testes, hypertrophy in the zona glomerulosa
of the adrenal cortex (both sexes), brush border loss in proximal tubular cells in the kidney (both sexes), and vacuolization of kidney tubular cells
(both sexes). The effects noted in the liver, testes, kidney, and adrenal were considered to be of a slight degree and occurred at a dose that clearly exceeded the maximum tolerated dose (MTD).
The overall NOEL following histological evaluation was considered to be 15 mg/kg bw/day (acid equivalent).
Effect levels
open allclose all
- Dose descriptor:
- NOEL
- Effect level:
- 15 mg/kg bw/day (nominal)
- Based on:
- act. ingr.
- Sex:
- male/female
- Basis for effect level:
- other: haematology; clinical chemistry; organ weights
- Dose descriptor:
- LOAEL
- Effect level:
- 100 mg/kg bw/day (nominal)
- Based on:
- act. ingr.
- Sex:
- male/female
- Basis for effect level:
- other: haematology; clinical chemistry; organ weights
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Table 1: Key results of the 13-week study in F344 rats on DMA
|
mg/kg/day (acid equivalents) |
||||
Control |
1 |
15 |
100 |
300 |
|
male |
|||||
Survival |
10/10 |
10/10 |
10/10 |
10/10 |
10/10 |
Body weight gain (g) |
173 ± 12 |
168 ± 18 |
172 ± 11 |
173 ± 15 |
100 ± 15* |
RBC counts (millions/µL) |
9.6 ± 0.2 |
9.6 ± 0.1 |
9.5 ± 0.3 |
9.5 ± 0.1 |
8.5 ± 0.1* |
Hemoglobin (g/dL) |
16.9 ± 0.4 |
16.9 ± 0.2 |
16.8 ± 0.4 |
16.8 ± 0.3 |
16.4 ± 0.2* |
Platelet counts (thousands/µL) |
854 ± 37 |
813 ± 138 |
833 ± 39 |
854 ± 90 |
708 ± 28* |
T3 levels (ng/dL) |
85.9 ± 21.7 |
99.9 ± 28.0 |
97.4 ± 16.4 |
89.4 ± 18.3 |
75.3 ± 17.8 |
T4 levels (µg/dL) |
3.9 ± 0.6 |
4.5 ± 0.5 |
4.2 ± 0.7 |
3.4 ± 0.6 |
1.0 ± 0.1* |
Thyroid/body weight ratio |
0.005 ± 0.001 |
0.006 ± 0.001 |
0.006 ± 0.001 |
0.006 ± 0 |
0.008 ± 0.002* |
Testes/body weight ratio |
1.41 ± 0.05 |
1.39 ± 0.05 |
1.42 ± 0.06 |
1.42 ± 0.11 |
0.80 ± 0.08* |
Kidney/body weight ratio |
0.67 ± 0.04 |
0.67 ± 0.03 |
0.71 ± 0.02 |
0.75 ± 0.03* |
0.77 ± 0.03* |
Liver/body weight ratio |
2.49 ± 0.16 |
2.51 ± 0.14 |
2.58 ± 0.16 |
2.58 ± 0.13 |
3.06 ± 0.25* |
Brush border loss of tubular cells |
0/10 |
0/10 |
0/10 |
0/10 |
7/10 |
Hypertrophy of adrenal cortex |
0/10 |
0/10 |
0/10 |
0/10 |
10/10 |
Centrilobular hepatocellular hypertrophy |
0/10 |
0/10 |
0/10 |
0/10 |
0/10 |
Females |
|||||
Survival |
10/10 |
10/10 |
10/10 |
10/10 |
9/10 |
Body weight gain (g) |
70 ± 9 |
75 ± 11 |
70 ± 6 |
61 ± 6 |
24 ± 14* |
RBC counts (millions/µL) |
9.0 ± 0.2 |
8.8 ± 0.2 |
9.0 ± 0.2 |
8.6 ± 0.1* |
7.8 ± 0.5* |
Hemoglobin (g/dL) |
16.7 ± 0.4 |
16.4 ± 0.4 |
16.7 ± 0.3 |
16.3 ± 0.3 |
15.4 ± 1.1* |
Platelet counts (thousands/µL) |
838 ± 62 |
882 ± 33 |
882 ± 36 |
705 ± 52* |
669 ± 31* |
BUN (mg/dL) |
17 ± 1.6 |
17 ± 1.1 |
17 ± 1.1 |
16 ± 1.7 |
21 ± 3.1* |
T3 levels (ng/dL) |
96.8 ± 14.9 |
92.9 ± 17.4 |
94.9 ± 11.7 |
75.7 ± 12.7* |
71.1 ± 19.8* |
T4 levels (µg/dL) |
2.7 ± 0.6 |
2.4 ± 0.5 |
2.5 ± 0.6 |
0.9 ± 0.1* |
0.9 ± 0.0* |
Thyroid/body weight ratio |
0.006 ± 0.001 |
0.008 ± 0.001 |
0.007 ± 0.003 |
0.008 ± 0.002 |
0.012 ± 0.003* |
Kidney/body weight ratio |
0.75 ± 0.05 |
0.73 ± 0.03 |
0.74 ± 0.05 |
0.80 ± 0.03 |
0.93 ± 0.10* |
Liver/body weight ratio |
2.72 ± 0.11 |
2.77 ± 0.10 |
2.73 ± 0.13 |
2.80 ± 0.11 |
4.10 ± 0.69* |
Cataracts |
0/10 |
0/10 |
0/10 |
0/10 |
7/10 |
Retinal degeneration |
0/10 |
0/10 |
0/10 |
0/10 |
6/10 |
Hypertrophy of adrenal cortex |
0/10 |
0/10 |
0/10 |
0/10 |
9/10 |
Brush border loss of tubular cells |
0/10 |
0/10 |
0/10 |
0/10 |
8/10 |
Centrilobular hepatocellular hypertrophy |
0/10 |
0/10 |
0/10 |
0/10 |
8/10 |
values reported are at the interval before study termination
* significantly different from the control value, p < 0.05
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.